Abstract
This article showed the data of ocular clinical parameters, tear fluid cytokines, and topical cyclosporine-A 0.1% (Ikervis®) compliance in allogeneic hematopoietic stem cell transplant (allo-HSCT) patients. Study visits were conducted at 3-5 weeks pre-allo-HSCT (screening), pre-allo-HSCT, and 3/6/12 months post-allo-HSCT, with data collected at each time point. At each visit, tear samples were assessed for 96 cytokines by the Proximity Extension Assay O-linked target 96 platform.